USING AI AND NEUROIMAGING

ADVANCED CLINICAL TRIALS AND THERAPIES

OPTIMIZED THERAPIES

OPTIMAL MEASURES

Qynapse is a medical technology company, spin-off of the CATI consortium of neuroimaging research laboratories.

Qynapse is a medical technology company, spin-off of the CATI consortium of neuroimaging research laboratories.

OUR CLIENTS

OUR CLIENTS

PHARMAS

A solution for supporting the data-driven selection of patients, monitoring drug performance and assessing the clinical trials outcomes.

HEALTHCARE PROVIDERS

A solution that offers early and extensive insights to assist in personalizing therapies for improved patient care.

NEWS

Qynapse receives FDA clearance for QyScore®, a novel imaging software for central nervous system diseases

/
QyScore® allows automated quantification of a broad portfolio of Magnetic Resonance Imaging markers that are key to support early diagnosis and clinical monitoring of neurodegenerative disorders

Qynapse exhibits at the 2019 Alzheimer’s Association International Conference (AAIC) in Los Angeles, CA

From July 14 – 18th, Qynapse will be part of the 2019 Alzheimer’s Association International Conference® (AAIC®) held in Los Angeles, California

Qynapse releases new validation results of QyScore performance

QyScore®, the software by Qynapse that provides automated volumetric measurements of brain structures, takes a big step forward with the validation of performance for one of its major functionalities

Qynapse attended the 14th AD/PD International Conference

Qynapse took part in the 2019 International Conference on Alzheimer’s & Parkinson’s Disease (AD/PDTM) in Lisbon, Portugal from March 26 – 31st